Study protocol for a randomised controlled trial: treatment of early intrauterine growth restriction with low molecular weight heparin (TRACIP)

Edurne Mazarico, Anna Peguero, Marta Camprubí, Carlota Rovira, Maria Dolores Gomez Roig, Daniel Oros, Patricia Ibáñez-Burillo, Jon Schoorlemmer, Narcís Masoller, Maria Dolors Tàssies, Francesc Figueras, Edurne Mazarico, Anna Peguero, Marta Camprubí, Carlota Rovira, Maria Dolores Gomez Roig, Daniel Oros, Patricia Ibáñez-Burillo, Jon Schoorlemmer, Narcís Masoller, Maria Dolors Tàssies, Francesc Figueras

Abstract

Introduction: The incidence of intrauterine growth restriction (IUGR) is estimated at about 3% of pregnancies, and it is associated with 30% of all perinatal mortality and severe morbidity with adverse neurodevelopmental and cardiovascular health consequences in adult life. Early onset IUGR represents 20%-30% of all cases and is highly associated with severe placental insufficiency. The existing evidence suggests that low molecular weight heparin (LMWH) has effects beyond its antithrombotic action, improving placental microvessel structure and function of pregnant women with vascular obstetric complications by normalising proangiogenic and antiapoptotic protein levels, cytokines and inflammatory factors. The objective of our study is to demonstrate the effectiveness of LMWH in prolonging gestation in pregnancies with early-onset IUGR.

Methods and analysis: This is a multicentre, triple-blind, parallel-arm randomised clinical trial. Singleton pregnancies qualifying for early (20-32 weeks at diagnosis) placental IUGR (according to Delphi criteria) will be randomised to subcutaneous treatment with bemiparin 3500 IU/0.2 mL/day or placebo from inclusion at diagnosis to the time of delivery. Analyses will be based on originally assigned groups (intention-to-treat). The primary objective will be analysed by comparing gestational age and prolongation of pregnancy (days) in each group with Student's t-tests for independent samples and by comparing Kaplan-Maier survival curves (from inclusion to delivery, log-rank test). A linear regression model for gestational age at birth will consider the following covariates: gestational age at inclusion (continuous) and pre-eclampsia (binary).

Ethics and dissemination: The study will be conducted in accordance with the principles of Good Clinical Practice. This study was approved by the Clinical Research Ethics Committee (CEIC) of Sant Joan de Déu Hospital, on 13 July 2017. The trial is registered in the public registry www.clinicaltrial.gov. according to Science Law 14/2011, and the results will be published in an open access journal.

Trial registration number: NCT03324139; Pre-results.

Keywords: fetal medicine; prenatal diagnosis; ultrasonography.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Figueras F, Gratacós E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther 2014;36:86–98. 10.1159/000357592
    1. Baschat AA, Cosmi E, Bilardo CM, et al. . Predictors of neonatal outcome in early-onset placental dysfunction. Obstet Gynecol 2007;109:253–61. 10.1097/01.AOG.0000253215.79121.75
    1. Fisher SJ. The placental problem: linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol 2004;2:53 10.1186/1477-7827-2-53
    1. Hossain N, Paidas MJ. Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies. Semin Perinatol 2007;31:208–12. 10.1053/j.semperi.2007.05.002
    1. Hecher K, Bilardo CM, Stigter RH, et al. . Monitoring of fetuses with intrauterine growth restriction: a longitudinal study. Ultrasound Obstet Gynecol 2001;18:564–70. 10.1046/j.0960-7692.2001.00590.x
    1. Cole TJ, Hey E, Richmond S. The PREM score: a graphical tool for predicting survival in very preterm births. Arch Dis Child Fetal Neonatal Ed 2010;95:F14–19. 10.1136/adc.2009.164533
    1. Abheiden C, Van Hoorn ME, Hague WM, et al. . Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial Doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG 2016;123 10.1111/1471-0528.13421
    1. Shomer E, Katzenell S, Zipori Y, et al. . Microvesicles of pregnant women receiving low molecular weight heparin improve trophoblast function. Thromb Res 2016;137:141–7. 10.1016/j.thromres.2015.11.026
    1. Shomer E, Katzenell S, Zipori Y, et al. . Microvesicles of women with gestational hypertension and preeclampsia affect human trophoblast fate and endothelial function. Hypertension 2013;62:893–8. 10.1161/HYPERTENSIONAHA.113.01494
    1. Dunk C, Ahmed A. Expression of VEGF-C and activation of its receptors VEGFR-2 and VEGFR-3 in trophoblast. Histol Histopathol 2001;16:359–75.
    1. Deng CL, Ling ST, Liu XQ, et al. . Decreased expression of matrix metalloproteinase-1 in the maternal umbilical serum, trophoblasts and decidua leads to preeclampsia. Exp Ther Med 2015;9:992–8. 10.3892/etm.2015.2194
    1. Azizieh FY, Raghupathy RG. Tumor necrosis factor-α and pregnancy complications: a prospective study. Med Princ Pract 2015;24:165–70. 10.1159/000369363
    1. Ishihara N, Matsuo H, Murakoshi H, et al. . Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 2002;186:158–66. 10.1067/mob.2002.119176
    1. Dodd JM, McLeod A, Windrim RC, et al. . Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2013;24:CD006780 10.1002/14651858.CD006780.pub3
    1. Roberge S, Demers S, Nicolaides KH, et al. . Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis. Ultrasound Obstet Gynecol 2016;47:548–53. 10.1002/uog.15789
    1. Rodger MA, Gris JC, de Vries JIP, et al. . Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet 2016;388:2629–41. 10.1016/S0140-6736(16)31139-4
    1. Kingdom JC, Walker M, Proctor LK, Shah M, et al. . Unfractionated heparin for second trimester placental insufficiency: a pilot randomized trial. J Thromb Haemost 2011;9:1483–92. 10.1111/j.1538-7836.2011.04407.x
    1. D’Souza R, Keating S, Walker M, et al. . Unfractionated heparin and placental pathology in high-risk pregnancies: secondary analysis of a pilot randomized controlled trial. Placenta 2014;35:816–23. 10.1016/j.placenta.2014.07.010
    1. Yu YH, Shen LY, Zhong M, et al. . [Effect of heparin on fetal growth restriction]. Zhonghua Fu Chan Ke Za Zhi 2004;39:793–6.
    1. Yu YH, Shen LY, Zou H, et al. . Heparin for patients with growth restricted fetus: a prospective randomized controlled trial. J Matern Fetal Neonatal Med 2010;23:980–7. 10.3109/14767050903443459
    1. Gordijn SJ, Beune IM, Thilaganathan B, et al. . Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol 2016;48:333–9. 10.1002/uog.15884
    1. Anon. Editrial/Pregnancy Hypertension. Int J Women Cardio Healt 2014;4:97–104.
    1. Figueras F, Meler E, Iraola A, et al. . Customized birthweight standards for a Spanish population. Eur J Obstet Gynecol Reprod Biol 2008;136:20–4. 10.1016/j.ejogrb.2006.12.015
    1. Gómez O, Figueras F, Fernández S, et al. . Reference ranges for uterine artery mean pulsatility index at 11-41 weeks of gestation. Ultrasound Obstet Gynecol 2008;32:128–32. 10.1002/uog.5315
    1. Arduini D, Rizzo G. Normal values of Pulsatility Index from fetal vessels: a cross-sectional study on 1556 healthy fetuses. J Perinat Med 1990;18:165–72. 10.1515/jpme.1990.18.3.165
    1. Baschat AA, Gembruch U. The cerebroplacental Doppler ratio revisited. Ultrasound Obstet Gynecol 2003;21:124–7. 10.1002/uog.20
    1. Hecher K, Campbell S, Snijders R, et al. . Reference ranges for fetal venous and atrioventricular blood flow parameters. Ultrasound Obstet Gynecol 1994;4:381–90. 10.1046/j.1469-0705.1994.04050381.x
    1. Robinson HP, Fleming JE. A critical evaluation of sonar crown-rump length measurements. Br J Obstet Gynaecol 1975;82:702–10. 10.1111/j.1471-0528.1975.tb00710.x
    1. Khong TY, Mooney EE, Ariel I, et al. . Sampling and definitions of placental lesions: Amsterdam placental workshop group consensus statement. Arch Pathol Lab Med 2016;140:698–713. 10.5858/arpa.2015-0225-CC

Source: PubMed

3
購読する